{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:21:21Z","timestamp":1790194881287,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"am","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.chest.2022.05.014","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T23:01:07Z","timestamp":1653174067000},"page":"693-700","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Treating Severe Refractory and Augmented Restless Legs Syndrome"],"prefix":"10.1016","volume":"162","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1673-5418","authenticated-orcid":false,"given":"John W.","family":"Winkelman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.chest.2022.05.014_bib1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1389-9457(03)00010-8","article-title":"Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology: a report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health","volume":"4","author":"Allen","year":"2003","journal-title":"Sleep Med"},{"issue":"11","key":"10.1016\/j.chest.2022.05.014_bib2","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/archinte.165.11.1286","article-title":"Restless legs syndrome prevalence and impact: REST General Population Study","volume":"165","author":"Allen","year":"2005","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.chest.2022.05.014_bib3","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/sleep\/32.6.772","article-title":"Polysomnographic and health-related quality of life correlates of restless legs syndrome in the Sleep Heart Health Study","volume":"32","author":"Winkelman","year":"2009","journal-title":"Sleep"},{"issue":"10","key":"10.1016\/j.chest.2022.05.014_bib4","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.sleep.2015.05.028","article-title":"Natural course of restless legs syndrome\/Willis\u2013Ekbom disease: long-term observation of a large clinical cohort","volume":"16","author":"Mitterling","year":"2015","journal-title":"Sleep Med"},{"issue":"12","key":"10.1016\/j.chest.2022.05.014_bib5","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1136\/jnnp.2010.211417","article-title":"Poor effect of guideline based treatment of restless legs syndrome in clinical practice","volume":"81","author":"Godau","year":"2010","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.chest.2022.05.014_bib6","doi-asserted-by":"crossref","first-page":"zsab212","DOI":"10.1093\/sleep\/zsab212","article-title":"High national rates of high-dose dopamine agonist prescribing for restless legs syndrome","volume":"45","author":"Winkelman","year":"2022","journal-title":"Sleep"},{"issue":"11","key":"10.1016\/j.chest.2022.05.014_bib7","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/archneur.1982.00510230065027","article-title":"Treatment of restless legs syndrome with levodopa plus benserazide","volume":"39","author":"Akpinar","year":"1982","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1016\/j.chest.2022.05.014_bib8","first-page":"CD006009","article-title":"Dopamine agonists for the treatment of restless legs syndrome","volume":"2011","author":"Scholz","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.chest.2022.05.014_bib9","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/sleep\/19.10.801","article-title":"Pergolide and carbidopa\/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients","volume":"19","author":"Earley","year":"1996","journal-title":"Sleep"},{"issue":"1","key":"10.1016\/j.chest.2022.05.014_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.sleep.2003.07.005","article-title":"Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS)","volume":"5","author":"Winkelman","year":"2004","journal-title":"Sleep Med"},{"issue":"5","key":"10.1016\/j.chest.2022.05.014_bib11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.smrv.2009.11.006","article-title":"Dopaminergic augmentation of restless legs syndrome","volume":"14","author":"Garc\u00eda-Borreguero","year":"2010","journal-title":"Sleep Med Rev"},{"issue":"7","key":"10.1016\/j.chest.2022.05.014_bib12","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/j.mayocp.2020.12.026","article-title":"The management of restless legs syndrome: an updated algorithm","volume":"96","author":"Silber","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"10.1016\/j.chest.2022.05.014_bib13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1303646","article-title":"Comparison of pregabalin with pramipexole for restless legs syndrome","volume":"370","author":"Allen","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.chest.2022.05.014_bib14","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1002\/mds.23771","article-title":"Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome: PSG study of gabapentin enacarbil in RLS","volume":"26","author":"Winkelman","year":"2011","journal-title":"Mov Disord"},{"issue":"10","key":"10.1016\/j.chest.2022.05.014_bib15","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1212\/WNL.59.10.1573","article-title":"Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study","volume":"59","author":"Garcia-Borreguero","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.chest.2022.05.014_bib16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.sleep.2018.11.025","article-title":"Reduced response to gabapentin enacarbil in restless legs syndrome following long-term dopaminergic treatment","volume":"55","author":"Garcia-Borreguero","year":"2019","journal-title":"Sleep Med"},{"key":"10.1016\/j.chest.2022.05.014_bib17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.sleep.2017.11.1126","article-title":"Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome\/Willis-Ekbom disease in adults and children: an IRLSSG task force report","volume":"41","author":"Allen","year":"2018","journal-title":"Sleep Med"},{"key":"10.1016\/j.chest.2022.05.014_bib18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.sleep.2016.07.028","article-title":"Iron and restless legs syndrome: treatment, genetics and pathophysiology","volume":"31","author":"Connor","year":"2017","journal-title":"Sleep Med"},{"key":"10.1016\/j.chest.2022.05.014_bib19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.sleep.2019.09.020","article-title":"Quantitative transcranial sonography of the substantia nigra as a predictor of therapeutic response to intravenous iron therapy in restless legs syndrome","volume":"66","author":"Garcia-Malo","year":"2020","journal-title":"Sleep Med"},{"issue":"12","key":"10.1016\/j.chest.2022.05.014_bib20","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1001\/archneur.56.12.1526","article-title":"Restless legs syndrome","volume":"56","author":"Winkelmann","year":"1999","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.chest.2022.05.014_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.mayocp.2017.11.007","article-title":"The appropriate use of opioids in the treatment of refractory restless legs syndrome","volume":"93","author":"Silber","year":"2018","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.chest.2022.05.014_bib22","doi-asserted-by":"crossref","first-page":"zsaa183","DOI":"10.1093\/sleep\/zsaa183","article-title":"Baseline and 1-year longitudinal data from the National Restless Legs Syndrome Opioid Registry","volume":"44","author":"Winkelman","year":"2021","journal-title":"Sleep"},{"issue":"5","key":"10.1016\/j.chest.2022.05.014_bib23","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.sleep.2010.11.002","article-title":"A\u00a010-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome","volume":"12","author":"Silver","year":"2011","journal-title":"Sleep Med"},{"issue":"5","key":"10.1016\/j.chest.2022.05.014_bib24","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40263-015-0250-2","article-title":"Long-term treatment of restless legs syndrome (RLS): an approach to management of worsening symptoms, loss of efficacy, and augmentation","volume":"29","author":"Mackie","year":"2015","journal-title":"CNS Drugs"},{"issue":"24","key":"10.1016\/j.chest.2022.05.014_bib25","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1212\/WNL.0000000000003388","article-title":"Practice guideline summary: treatment of restless legs syndrome in adults: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"87","author":"Winkelman","year":"2016","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.chest.2022.05.014_bib26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.sleep.2011.09.013","article-title":"Efficacy and safety of dopamine agonists in restless legs syndrome","volume":"13","author":"Hornyak","year":"2012","journal-title":"Sleep Med"},{"issue":"1","key":"10.1016\/j.chest.2022.05.014_bib27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40264-017-0590-6","article-title":"Dopamine agonists and impulse control disorders: a complex association","volume":"41","author":"Grall-Bronnec","year":"2018","journal-title":"Drug Saf"},{"issue":"3","key":"10.1016\/j.chest.2022.05.014_bib28","article-title":"Opioids and their endocrine effects: a systematic review and meta-analysis","volume":"105","author":"de Vries","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.chest.2022.05.014_bib29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.sleep.2011.09.015","article-title":"Breakthrough symptoms during the daytime in patients with restless legs syndrome (Willis-Ekbom disease)","volume":"13","author":"Tzonova","year":"2012","journal-title":"Sleep Med"},{"issue":"5","key":"10.1016\/j.chest.2022.05.014_bib30","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.sleep.2011.03.003","article-title":"Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample","volume":"12","author":"Allen","year":"2011","journal-title":"Sleep Med"},{"key":"10.1016\/j.chest.2022.05.014_bib31","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.sleep.2018.10.014","article-title":"Validation of the self-administered version of the international Restless Legs Syndrome study group severity rating scale\u2014the sIRLS11","volume":"54","author":"Sharon","year":"2019","journal-title":"Sleep Med"},{"issue":"11","key":"10.1016\/j.chest.2022.05.014_bib32","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1136\/gutjnl-2021-325210","article-title":"British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults","volume":"70","author":"Snook","year":"2021","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.chest.2022.05.014_bib33","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jpsychires.2008.02.006","article-title":"Restless legs syndrome as side effect of second generation antidepressants","volume":"43","author":"Rottach","year":"2008","journal-title":"J\u00a0Psychiatr Res"},{"issue":"2","key":"10.1016\/j.chest.2022.05.014_bib34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/11317500-000000000-00000","article-title":"Depressive disorders in restless legs syndrome: epidemiology, pathophysiology and management","volume":"24","author":"Hornyak","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.chest.2022.05.014_bib35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jsat.2016.10.001","article-title":"Prevalence of restless legs syndrome during detoxification from alcohol and opioids","volume":"73","author":"Mackie","year":"2017","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"153","key":"10.1016\/j.chest.2022.05.014_bib36","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0061-2019","article-title":"Treating restless legs syndrome in the context of sleep disordered breathing comorbidity","volume":"28","author":"Romero-Peralta","year":"2019","journal-title":"Eur Respir Rev"},{"issue":"2","key":"10.1016\/j.chest.2022.05.014_bib37","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5935\/1984-0063.20190064","article-title":"Exercise as a favorable non-pharmacologic treatment to sleep-related movement disorders: a review","volume":"12","author":"Franco","year":"2019","journal-title":"Sleep Sci"},{"issue":"5","key":"10.1016\/j.chest.2022.05.014_bib38","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.sleep.2007.03.022","article-title":"Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group Consensus Conference at the Max Planck Institute","volume":"8","author":"Garc\u00eda-Borreguero","year":"2007","journal-title":"Sleep Med"},{"key":"10.1016\/j.chest.2022.05.014_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.sleep.2016.01.017","article-title":"Guidelines for the first-line treatment of restless legs syndrome\/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation","volume":"21","author":"Garcia-Borreguero","year":"2016","journal-title":"Sleep Med"},{"key":"10.1016\/j.chest.2022.05.014_bib40","doi-asserted-by":"crossref","unstructured":"Laiwah JY, Winkelman JW. How effective are treatment guidelines for augmented RLS [published online ahead of print May 9, 2022]? Sleep. https:\/\/doi.org\/10.1093\/sleep\/zsac108.","DOI":"10.1093\/sleep\/zsac108"},{"issue":"6","key":"10.1016\/j.chest.2022.05.014_bib41","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1526-4637.2005.00072.x","article-title":"Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool","volume":"6","author":"Webster","year":"2005","journal-title":"Pain Med"},{"issue":"4","key":"10.1016\/j.chest.2022.05.014_bib42","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.chest.2016.05.022","article-title":"Opioids and sleep-disordered breathing","volume":"150","author":"Van Ryswyk","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.chest.2022.05.014_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2021.101441","article-title":"The relationship between opioid use and obstructive sleep apnea: a systematic review and meta-analysis","volume":"58","author":"Ahmad","year":"2021","journal-title":"Sleep Med Rev"},{"issue":"2","key":"10.1016\/j.chest.2022.05.014_bib44","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/thoraxjnl-2018-211675","article-title":"The effect of acute morphine on obstructive sleep apnoea: a randomised double-blind placebo-controlled crossover trial","volume":"74","author":"Rowsell","year":"2019","journal-title":"Thorax"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001236922201008X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001236922201008X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T07:43:33Z","timestamp":1715240613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001236922201008X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S001236922201008X"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2022.05.014","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treating Severe Refractory and Augmented Restless Legs Syndrome","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2022.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}